141 related articles for article (PubMed ID: 38281871)
1. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data.
Tang J; Li Q; Huang Z; Shi L; Guo Q; Li M; Gao X; Chao K
Dig Liver Dis; 2024 May; 56(5):749-755. PubMed ID: 38281871
[TBL] [Abstract][Full Text] [Related]
2. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
Ten Bokkel Huinink S; Biemans V; Duijvestein M; Pierik M; Hoentjen F; West RL; van der Woude CJ; de Vries AC
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e783-e788. PubMed ID: 34334713
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
6. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
[TBL] [Abstract][Full Text] [Related]
7. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY).
Shehab M; Abdullah I; Alfadhli A; Alrashed F
Medicine (Baltimore); 2024 Jul; 103(27):e38804. PubMed ID: 38968490
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
14. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
Rowan CR; Keegan D; Byrne K; Cullen G; Mulcahy HE; Sheridan J; Ryan EJ; de Vries A; D'Haens G; Doherty GA
Aliment Pharmacol Ther; 2018 Aug; 48(3):333-339. PubMed ID: 29920697
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
